Mortality, Length of Stay, and Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Elderly Hospitalized Patients in the United States

Richard E Nelson, David Hyun, Amanda Jezek, Matthew H Samore, Richard E Nelson, David Hyun, Amanda Jezek, Matthew H Samore

Abstract

Background: This study reports estimates of the healthcare costs, length of stay, and mortality associated with infections due to multidrug-resistant bacteria among elderly individuals in the United States.

Methods: We conducted a retrospective cohort analysis of patients aged ≥65 admitted for inpatient stays in the Department of Veterans Affairs healthcare system between 1/2007-12/2018. We identified those with positive cultures for multidrug-resistant bacteria and matched each infected patient to ≤10 control patients. We then performed multivariable regression models to estimate the attributable cost and mortality due to the infection. We also constructed multistate models to estimate the attributable length of stay due to the infection. Finally, we multiplied these pathogen-specific attributable cost, length of stay, and mortality estimates by national case counts from hospitalized patients in 2017.

Results: Our cohort consisted of 87 509 patients with infections and 835 048 matched controls. Costs were higher for hospital-onset invasive infections, with attributable costs ranging from $22 293 (95% confidence interval: $19 101-$24 485) for methicillin-resistant Staphylococcus aureus (MRSA) to $57 390 ($34 070-$80 710) for carbapenem-resistant (CR) Acinetobacter. Similarly, for hospital-onset invasive infections, attributable mortality estimates ranged from 14.2% (12.2-16.2%) for MRSA to 24.1% (12.1-36.0%) for CR Acinetobacter. The aggregate cost of these infections was an estimated $1.9 billion ($1.3 billion-$2.5 billion) with 11 852 (8719-14 985) deaths and 448 224 (354 513-541 934) inpatient days in 2017.

Conclusions: Efforts to prevent these infections due to multidrug-resistant bacteria could save a significant number of lives and healthcare resources.

Keywords: antimicrobial resistance; healthcare-associated infections; mortality; veterans.

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Unadjusted mean hospital costs per patient by pathogen type and onset. Abbreviations: CR, carbapenem-resistant; CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum β-lactamase; MDR, multidrug-resistant; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant Enterococcus.
Figure 2.
Figure 2.
Unadjusted 30-day probability of mortality by pathogen type and onset. Abbreviations: CR, carbapenem-resistant; CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum β-lactamase; MDR, multidrug-resistant; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant Enterococcus.

References

    1. Smith PW, Bennett G, Bradley S, et al. ; Society for Healthcare Epidemiology of America; Association for Professionals in Infection Control and Epidemiology. SHEA/APIC guideline: infection prevention and control in the long-term care facility, July 2008. Infect Control Hosp Epidemiol 2008; 29:785-814.
    1. Detweiler K, Mayers D, Fletcher SG. Bacteruria and urinary tract infections in the elderly. Urol Clin North Am 2015; 42:561-8.
    1. Esposito S, Leone S, Noviello S, Lanniello F, Fiore M. Antibiotic resistance in long-term care facilities. New Microbiol 2007; 30:326-31.
    1. Mouton CP, Bazaldua OV, Pierce B, Espino DV. Common infections in older adults. Am Fam Physician 2001; 63:257-68.
    1. Peron EP, Hirsch AA, Jury LA, Jump RL, Donskey CJ. Another setting for stewardship: high rate of unnecessary antimicrobial use in a veterans affairs long-term care facility. J Am Geriatr Soc 2013; 61:289-90.
    1. van Buul LW, van der Steen JT, Veenhuizen RB, et al. . Antibiotic use and resistance in long term care facilities. J Am Med Dir Assoc 2012; 13:568.e1-13.
    1. Vespa J. The US joins other countries with arge aging populations.2018. Available at: . Accessed 12 June 2020.
    1. US Department of Health and Human Services. Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB). Available at: . Accessed 2 March 2020.
    1. US White House. National action plan for combating antiobiotic-resistant bacteria. Washington, DC: US White House, 2015.
    1. Her Majesty’s Government. Tackling antimicrobial resistance: 2019–2024. The UK’s five-year national action plan. London, UK: HM Government, 2019.
    1. O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Resistanc; e; 2014. Available at: .
    1. Organisation for Economic Co-operation and Development. Antimicrobial resistance: tackling the burden in the European Union.Brussels, Belgium: OECD, 2019.
    1. Stemming the superbug tide: just a few dollars more. Paris, France: OECD Health Policy Studies, 2018. Available at: .
    1. Jonas OB, Irwin A, Berthe FCJ, Le Gall FG, Marquez PV.. Drug-resistant infections: a threat to our economic future. Washington, DC: World Bank Group, 2017.
    1. Global action plan on antimicrobial resistance. Geneva, Switzerland: World Health Organization, 2015.
    1. Jones M, DuVall SL, Spuhl J, Samore MH, Nielson C, Rubin M. Identification of methicillin-resistant Staphylococcus aureus within the nation’s Veterans Affairs medical centers using natural language processing. BMC Med Inform Decis Mak 2012; 12:34.
    1. Wagner T, Chow A, Su P, Barnett PG.. HERC’s average cost datasets for VA inpatient care, FY1998-FY2016. Guidebook. Palo Alto, California: VA Palo Alto Health Economics Resource Center, 2017.
    1. Matsumura JS, Stroupe KT, Lederle FA, Kyriakides TC, Ge L, Freischlag JA; Open Versus Endovascular Repair (OVER) Veterans Affairs Cooperative Study Group. . Costs of repair of abdominal aortic aneurysm with different devices in a multicenter randomized trial. J Vasc Surg 2015; 61:59-65.
    1. Wagner TH, Upadhyay A, Cowgill E, et al. . Risk adjustment tools for learning health systems: a comparison of DxCG and CMS-HCC V21. Health Serv Res 2016; 51:2002-19.
    1. Wagner TH, Chen S, Barnett PG. Using average cost methods to estimate encounter-level costs for medical-surgical stays in the VA. Med Care Res Rev 2003; 60:15S-36S.
    1. Nelson RE, Slayton RB, Stevens VW, et al. . Attributable mortality of healthcare-associated infections due to multidrug-resistant gram-negative bacteria and methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2017; 38:848-56.
    1. Nelson RE, Stevens VW, Jones M, Samore MH, Rubin MA. Health care-associated methicillin-resistant Staphylococcus aureus infections increases the risk of postdischarge mortality. Am J Infect Control 2015; 43:38-43.
    1. Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv Res 2018; 53:175-96.
    1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, CDC, 2019.
    1. Jernigan JA, Hatfield KM, Wolford H, et al. . Multidrug-resistant bacterial infections, US hospitalized patients, 2012–17. N Engl J Med 2020; 382:1309-19.
    1. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011; 64:749-59.
    1. Wolkewitz M, Beyersmann J, Gastmeier P, Schumacher M. Efficient risk set sampling when a time-dependent exposure is present: matching for time to exposure versus exposure density sampling. Methods Inf Med 2009; 48:438-43.
    1. Mihaylova B, Briggs A, O’Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ 2011; 20:897-916.
    1. Manning WG. Dealing with skewed data on costs and expenditures. In: Jones A, ed. The Elgar companion to health economics. Cheltenham, UK: E. Elgar Publishing, 2012:473-80.
    1. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20:461-94.
    1. Graves N, Harbarth S, Beyersmann J, Barnett A, Halton K, Cooper B. Estimating the cost of health care-associated infections: mind your p’s and q’s. Clin Infect Dis 2010; 50:1017-21.
    1. Page K, Barnett AG, Graves N. What is a hospital bed day worth? A contingent valuation study of hospital chief executive officers. BMC Health Serv Res 2017; 17:137.
    1. Stewardson AJ, Harbarth S, Graves N; TIMBER Study Group. . Valuation of hospital bed-days released by infection control programs: a comparison of methods. Infect Control Hosp Epidemiol 2014; 35:1294-7.
    1. Nelson RE, Hatfield KM, Wolford H, et al. . National estimates of healthcare costs associated with multidrug-resistant bacterial infections among hospitalized patients in the United States. Clin Infect Dis 2021; 72:17-26.
    1. Jernigan JA, Hatfield KM, Wolford H, et al. . Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017. N Engl J Med 2020; 382:1309-19.
    1. de Kraker MEA, Lipsitch M. Burden of antimicrobial resistance: compared to what? Epidemiol Rev 2021. Available at: .
    1. Nelson RE, Jones M, Liu CF, et al. . The impact of healthcare-associated methicillin-resistant Staphylococcus aureus infections on post-discharge healthcare costs and utilization. Infect Control Hosp Epidemiol 2015; 36:534-42.
    1. Nelson RE, Jones M, Liu CF, et al. . The impact of healthcare-associated methicillin-resistant staphylococcus aureus infections on postdischarge health care costs and utilization across multiple health care systems. Health Serv Res 2018; 53(Suppl 3):5419-37.
    1. Wozniak TM, Barnsbee L, Lee XJ, Pacella RE. Using the best available data to estimate the cost of antimicrobial resistance: a systematic review. Antimicrob Resist Infect Control 2019; 8:26.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera